SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 272 filers reported holding SAGE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $5,092,000 | -4.0% | 119,702 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $5,304,000 | -24.0% | 119,702 | -2.5% | 0.00% | -20.0% |
| Q2 2021 | $6,975,000 | -26.9% | 122,783 | -3.7% | 0.01% | -28.6% |
| Q1 2021 | $9,546,000 | -15.1% | 127,532 | -1.8% | 0.01% | -22.2% |
| Q4 2020 | $11,239,000 | +71.4% | 129,918 | +21.1% | 0.01% | +50.0% |
| Q3 2020 | $6,558,000 | +51.4% | 107,300 | +3.0% | 0.01% | +50.0% |
| Q2 2020 | $4,333,000 | +44.1% | 104,200 | -0.5% | 0.00% | 0.0% |
| Q1 2020 | $3,007,000 | -62.9% | 104,700 | -6.8% | 0.00% | -42.9% |
| Q4 2019 | $8,107,000 | -38.4% | 112,304 | +19.7% | 0.01% | -46.2% |
| Q3 2019 | $13,158,000 | +19.4% | 93,788 | +55.8% | 0.01% | 0.0% |
| Q2 2019 | $11,022,000 | +12.5% | 60,200 | -2.3% | 0.01% | +8.3% |
| Q1 2019 | $9,797,000 | +63.4% | 61,600 | -1.6% | 0.01% | +50.0% |
| Q4 2018 | $5,996,000 | -29.9% | 62,600 | +3.4% | 0.01% | -27.3% |
| Q3 2018 | $8,552,000 | -15.4% | 60,545 | -6.3% | 0.01% | -21.4% |
| Q2 2018 | $10,111,000 | -9.9% | 64,596 | -7.3% | 0.01% | -12.5% |
| Q1 2018 | $11,221,000 | -8.8% | 69,665 | -6.7% | 0.02% | -5.9% |
| Q4 2017 | $12,297,000 | +1454.6% | 74,660 | +487.9% | 0.02% | +1600.0% |
| Q3 2017 | $791,000 | +24.2% | 12,699 | +58.7% | 0.00% | 0.0% |
| Q2 2017 | $637,000 | +12.0% | 8,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $569,000 | +32.6% | 8,000 | -4.8% | 0.00% | 0.0% |
| Q4 2016 | $429,000 | +10.9% | 8,400 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $387,000 | +41.2% | 8,400 | -7.7% | 0.00% | – |
| Q2 2016 | $274,000 | -9.0% | 9,100 | -3.2% | 0.00% | – |
| Q1 2016 | $301,000 | -48.4% | 9,400 | -6.0% | 0.00% | -100.0% |
| Q4 2015 | $583,000 | +37.8% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $423,000 | -42.1% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $730,000 | -13.5% | 10,000 | -52.7% | 0.00% | 0.0% |
| Q1 2015 | $844,000 | 0.0% | 21,121 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $844,000 | +42.1% | 21,121 | +12.0% | 0.00% | 0.0% |
| Q3 2014 | $594,000 | – | 18,850 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |